AngioDynamics Secures 510(k) Clearance For AlphaVac F1885 System In Treatment Of Pulmonary Embolism
Portfolio Pulse from Benzinga Newsdesk
AngioDynamics has received FDA 510(k) clearance for its AlphaVac F1885 System for the treatment of pulmonary embolism (PE), expanding its applicability in the non-surgical removal of thrombi or emboli from the venous vasculature. This clearance broadens treatment options for PE patients, aiming to reduce thrombus burden and improve right ventricular function.
April 04, 2024 | 10:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AngioDynamics' AlphaVac F1885 System has been granted FDA 510(k) clearance for the treatment of pulmonary embolism, expanding its usage in non-surgical thrombi or emboli removal.
The FDA 510(k) clearance for AngioDynamics' AlphaVac F1885 System for pulmonary embolism treatment is a significant positive development. It not only broadens the system's applicability but also positions AngioDynamics favorably in the market for non-surgical thrombi or emboli removal solutions. This regulatory milestone could lead to increased adoption and sales of the AlphaVac F1885 System, positively impacting AngioDynamics' financial performance and stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100